MedTrace Logo

Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS

NCT04165850 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2021-03-03

No results posted yet for this study

Summary

This is an open label, off label study, to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability and routine disease progression measures (ALSFRS-R and Vital Capacity).

Conditions

Interventions

DRUG

Fixed dose combination Ciprofloxacin/Celecoxib

Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day

Sponsors & Collaborators

  • NeuroSense Therapeutics Ltd.

    lead INDUSTRY

Principal Investigators

  • Vivian Drory, MD · Sourasky Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-25
Primary Completion
2021-01-19
Completion
2021-01-19

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04165850 on ClinicalTrials.gov